Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Aumolertinib”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Looking for participantsNCT06951464
What this trial is testing

BL-B01D1 and Almonertinib in Patients With Resectable EGFR+ Stage II-IIIB NSCLC

Who this might be right for
Non-Small Cell Lung Cancer
Sichuan University 40
Testing effectiveness (Phase 2)UnknownNCT04755738
What this trial is testing

Almonertinib Plus Microwave Ablation in Advanced Non-small Cell Lung Cancer

Who this might be right for
Advanced Non Small Cell Lung Cancer
Qianfoshan Hospital 234
Testing effectiveness (Phase 2)UnknownNCT04354961
What this trial is testing

Almonertinib as First-line Treatment in Patients With EGFR+ Positive Pulmonary Adenosquamous Carcinoma or Combined Adenocarcinoma and Squamous Cell Carcinoma

Who this might be right for
Pulmonary Adenosquamous Carcinoma
Fujian Cancer Hospital 13
Testing effectiveness (Phase 2)UnknownNCT04808752
What this trial is testing

Almonertinib as First-line Treatment in Patients With EGFR Mutations Positive in Advanced NSCLC With Brain Metastases

Who this might be right for
Lung Cancer
Zhejiang Cancer Hospital 63
Not applicableUnknownNCT06481566
What this trial is testing

Efficacy and Safety of Almonertinib Combined With Stereotactic Body Radiotherapy (SBRT) in the Treatment of Non-small Cell Lung Cancer With EGFR Sensitive Mutation: a Single-arm, Open-label Clinical Trial

Who this might be right for
Non-small Cell Lung Cancer
Chongqing University Cancer Hospital 30
Not applicableLooking for participantsNCT06102928
What this trial is testing

A Clinical Study of the Combination of Anlotinib and Aumolertinib in the First-line Treatment of Advanced NSCLC With EGFR 21L858R Mutation

Who this might be right for
Non-Small Cell Lung Cancer With Mutation in Epidermal Growth Factor Receptor
Kunming Medical University 30
Early research (Phase 1)UnknownNCT05223595
What this trial is testing

Gentuximab in Combination With Almonertinib in EGFR Mutation-positive Metastatic NSCLC

Who this might be right for
Metastatic Non-Small Cell Lung Cancer
Changchun GeneScience Pharmaceutical Co., Ltd. 42
Large-scale testing (Phase 3)UnknownNCT05994339
What this trial is testing

Radiotherapy Combined With Almonertinib for Stage III EGFR-Mutated Lung Cancer

Who this might be right for
Lung Cancer Stage III
Laibin People's Hospital 40
Early research (Phase 1)UnknownNCT05826483
What this trial is testing

Almonertinib in the First-line Treatment of Patients of NSCLC With Poor Performance Status

Who this might be right for
Malignant Tumor of LungPoor Performance Status
Guangzhou Institute of Respiratory Disease 20
Large-scale testing (Phase 3)UnknownNCT04500717
What this trial is testing

Almonertinib Plus Chemotherapy as First-line Treatment in Patients With EGFR Concomitant Tumor Suppressor Gene Mutation

Who this might be right for
Non Small Cell Lung Cancer
Cancer Institute and Hospital, Chinese Academy of Medical Sciences 460
Early research (Phase 1)Looking for participantsNCT06926413
What this trial is testing

A Study Evaluating the Effect of Aumolertinib on the Pharmacokinetics of Midazolam in Patients With NSCLC

Who this might be right for
Non Small Cell Lung Cancer
Jiangsu Hansoh Pharmaceutical Co., Ltd. 20
Early research (Phase 1)UnknownNCT05430386
What this trial is testing

Study of HS-10241 in Combination With Almonertinib in Patients With Locally Advanced or Metastatic NSCLC

Who this might be right for
Non Small Cell Lung Cancer
Jiangsu Hansoh Pharmaceutical Co., Ltd. 174
Testing effectiveness (Phase 2)UnknownNCT04636593
What this trial is testing

Trial of Almonertinib With Concurrent Radiotherapy in The Treatment of Local Advanced EGFR-mutant NSCLC

Who this might be right for
Non Small Cell Lung CancerStage III NSCLCEGFR Activating Mutation
First People's Hospital of Hangzhou 43
Testing effectiveness (Phase 2)Not Yet RecruitingNCT05778149
What this trial is testing

Safety and Efficacy of Aumolertinib Combined With Anlotinib as 1st Line Treatment in Advanced Lung Cancer EGFR Mutation With TP53 Co-Mutation

Who this might be right for
AumolertinibAnlotinibTP53+2 more
Tianjin Medical University Cancer Institute and Hospital 47
Early research (Phase 1)Looking for participantsNCT07130916
What this trial is testing

Aumolertinib in European Participants With Non-Small Cell Lung Cancer

Who this might be right for
Non-Small Cell Lung Cancer
Jiangsu Hansoh Pharmaceutical Co., Ltd. 20
Large-scale testing (Phase 3)Active Not RecruitingNCT04841811
What this trial is testing

MDT-bridged Radical Therapy After Aumolertinib With MRD-guided Maintenance in EGFRm+ Unresectable Stage III NSCLC (APPROACH)

Who this might be right for
Lung Cancer
Guangdong Association of Clinical Trials 192
Testing effectiveness (Phase 2)UnknownNCT06463171
What this trial is testing

Phase II Trial of Almonertinib Plus Lastet for EGFR+ Non-small Cell Lung Cancer

Who this might be right for
Lung Cancer Non-small Cell Stage IV
Shanghai Pulmonary Hospital, Shanghai, China 60
Testing effectiveness (Phase 2)Looking for participantsNCT07624487
What this trial is testing

Aumolertinib Combined With Phased Chemotherapy for EGFR L858R Lung Adenocarcinoma

Who this might be right for
Lung Adenocarcinoma Metastatic
Taipei Medical University Hospital 50
Large-scale testing (Phase 3)Looking for participantsNCT05768490
What this trial is testing

Early or Delayed Intervention of Brain Radiotherapy Combined With Almonertinib in EGFR Mutated NSCLC With Brain Metastases

Who this might be right for
Brain MetastasesRadiotherapyEGFR Activating Mutation
Sun Yat-sen University 232
Large-scale testing (Phase 3)UnknownNCT04870190
What this trial is testing

Almonertinib Versus Osimertinib in the Patients With EGFR Mutations in Advanced NSCLC With Brain Metastases

Who this might be right for
NSCLC
Shanghai Chest Hospital 232
Next Page